Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy.
An analysis of clinical records after the introduction of highly active antiretroviral therapy (HAART) in Mexico showed a lower prevalence and severity of immune recovery uveitis when HIV-infected patients started HAART after completing cytomegalovirus retinitis treatment than when treatments were concomitant. The findings suggest a protective role of delaying HAART until cytomegalovirus retinitis is controlled.